Following a brief academic career at Université Laval in the early 90s, Martin Godbout was named President and General Manager of Société Innovatech Québec. In 1997, he pursued his career in the biopharmaceutical venture capital sector as Senior Vice-President of BioCapital. In May 2000, he became the founding President and CEO of Genome Canada, which he led for nearly 10 years.
Officer of the Order of Canada (2005), Mr. Godbout is currently Chair of the Board of AmorChem, BioContact, BIOQuébec and Génome Québec. He is also and independent Board member of the following organizations: AngioChem, Asmacure, Chelation Partners, Fonds de recherche du Québec – Santé, Montréal InVivo, P3G, the Ataxia Charlevoix-Saguenay Foundation, the Foundation of Stars and the Leukodystrophies Foundation.
Mr. Godbout holds a Ph.D. in Physiology and Molecular Endocrinology from Université Laval and completed postdoctoral training in neuromolecular biology at the Scripps Research Institute in San Diego.